What Sponsors and CROs Look for in a Research Site Before Selection

Research Sites often ask, “How can we win more Studies?” A better starting point is “What makes a Sponsor or CRO confident enough to choose us?” Those are not exactly the same question. A Site can market aggressively, attend conferences, send capabilities decks, and build strong business-development relationships. But once a real Study opportunity appears, the Sponsor must evaluate risk.

They need confidence that the Site can identify the right participants, activate on time, follow the protocol, maintain adequate staffing, produce reliable data, communicate effectively, and enroll enough participants to justify activation. Site selection is therefore not a beauty contest. It is a risk-management decision.

Sponsors Are Trying to Predict Performance

The fundamental Site-selection problem is simple: Sponsors must choose Sites before they know how those Sites will perform on the Study. They are trying to predict future execution using available evidence — historical performance, patient population, investigators, staff, recruitment capability, infrastructure, responsiveness, the local healthcare environment, and protocol fit.

A 2026 paper in Therapeutic Innovation & Regulatory Science, based on interviews with Sponsors, CROs, and Sites plus a literature review, argues that current selection approaches are often predictive and profile-based, and that Sites with similar profiles can perform inconsistently. It proposes a framework that distinguishes between site inputs (resources and operating environment), dynamic capabilities (coordinated site-level abilities), and outputs (performance metrics), and it points to a circular-reasoning problem in feasibility projections, where Sites self-assess their own performance potential (Therapeutic Innovation & Regulatory Science, 2026). For Research Sites, this means one thing: the stronger the evidence you provide, the easier you are to evaluate.

1. Recruitment Capability

Participant recruitment remains one of the most important considerations. A 2019 survey published in Trials analyzed 83 responses from site-selection decision-makers in the Nordic countries at multinational biopharmaceutical companies and CROs. Among them, 84% strongly agreed or agreed that recruitment-related factors are the site-related qualities their company values the most, and 71% ranked recruitment and retention track record first when asked which information about an unfamiliar trial site they would find most valuable (Trials, 2019). It is a regional survey, so it is an indicator rather than a universal rule — but it is consistent with what Sites hear from Sponsors.

Sponsors want to understand whether the Site can identify potential participants, whether it has access to the required population, whether it has multiple recruitment channels, whether it has performed in similar Studies, and whether it can respond when enrollment slows. A Site that simply says “We have a large database” provides less confidence than a Site that can explain its recruitment system.

Patient Counts Are Not Enough

Sponsors frequently ask Sites for estimated patient numbers. Those numbers can be useful, but patient access is more complicated than a database count. The Site Assessment Survey Instrument (SASI) published in 2024 goes beyond simple patient counts to ask operational and situational questions, including whether the PI can commit a specific amount of effort to study activities and to recruiting culturally diverse patients, whether cultural and language competence training is provided, the clinic’s hours of operation, and the ease of referral (Contemporary Clinical Trials, 2024). That means 10,000 database records does not automatically equal 10,000 recruitable participants. Sponsors increasingly need evidence of actual recruitment access.

2. Investigator Commitment

A highly qualified investigator is valuable. But Sponsors also need to know whether the PI will actually participate. The SASI asks for estimates of investigator effort and of the site coordinator time protected for trial tasks (Contemporary Clinical Trials, 2024). A prestigious PI with little operational involvement can create more risk than a less famous investigator who is deeply engaged.

PI Enthusiasm Matters

An investigator who believes the research question is relevant to clinical practice may recruit more effectively, engage referring physicians, support coordinators, address operational problems, and remain involved throughout the Study. The same instrument asks investigators to rate the enthusiasm and eagerness of their teams to participate, because recruitment can be harder when investigators are conflicted in their dual roles as clinicians and researchers. That commitment can be difficult to measure, but Sponsors look for signals during feasibility, Site qualification visits, and investigator conversations.

3. Research Team Experience

The PI does not execute the Study alone. Sponsors evaluate the broader team, which may include coordinators, regulatory personnel, recruiters, pharmacists, laboratory staff, and Site management. Standardized Site-assessment approaches ask about coordinator assignments, team track records, and the ability to meet Study timelines. A strong Site demonstrates that there is an actual team behind the investigator.

Staff Stability Matters

Sponsors may also evaluate whether the Site can maintain continuity. High staff turnover can create retraining, delayed visits, inconsistent documentation, and communication gaps. Sites that build stable, well-defined roles may reduce perceived operational risk.

4. Protocol Fit

A good Site in general is not automatically a good Site for every protocol. Sponsors need to assess whether this Site fits this specific Study. Protocol-specific feasibility can include the patient population, referral patterns, standard of care, competing Studies, required procedures, equipment, staffing, and visit schedule. A 2024 paper from an industry Site Feasibility Task Force of Sponsors, CROs, and Sites explicitly separates general Site profile, capability, and performance from protocol-specific assessment (Contemporary Clinical Trials Communications, 2024). That distinction is critical.

A Site Should Know When the Protocol Is a Poor Fit

Sponsors often appreciate Sites that evaluate realistically. A Site that accepts everything may create doubt. Professional feasibility sometimes means saying “This Study is not a strong fit for us,” and that can preserve long-term credibility.

5. Historical Recruitment Performance

Past performance does not guarantee future performance, but it provides useful evidence. Sponsors may look at enrollment against target, recruitment velocity, retention, screen failure, and time to first participant. The SASI authors note that site performance has been correlated with past trial performance, and their survey asks about past performance in reaching enrollment goals (Contemporary Clinical Trials, 2024). Sites should therefore track these metrics consistently.

Build an internal performance history. For each Study, record the target, actual enrollment, activation date, enrollment period, retention, and screen failure. This turns past Studies into future business-development evidence.

6. Ability to Meet Timelines

Clinical trials operate under schedules. Sponsors may care about feasibility turnaround, startup, regulatory submission, contract execution, first participant, and recruitment milestones. The SASI explicitly assesses the feasibility of tight timelines as a selection factor (Contemporary Clinical Trials, 2024). Slow responsiveness can become an early warning signal.

Responsiveness Begins Before Site Selection

The feasibility process itself is part of the evaluation. If a Site takes days to acknowledge messages, misses deadlines, or returns incomplete forms, the Sponsor may reasonably wonder whether the same thing will happen during the Study. The Site Feasibility Task Force paper makes the practical consequence explicit: Sponsors and CROs cannot accurately assess potential Site lists or plan startup timelines when Sites do not respond, and Sites may be replaced by more responsive Sites (Contemporary Clinical Trials Communications, 2024). Business-development behavior can become a preview of Site operations.

7. Site Infrastructure

Sponsors need confidence that the Site has the physical and operational resources required. Depending on the protocol, that may include exam rooms, a laboratory, a pharmacy, investigational product storage, temperature monitoring, a centrifuge, ECG, specialized equipment, secure records, and participant areas.

A 2023 framework for assessing clinical trial site readiness, developed by a group of clinical trial experts from existing Sponsor site qualifications, organizes readiness into six domains: research team, infrastructure, study management, data collection and management, quality oversight, and ethics and safety (Journal of Clinical and Translational Science, 2023). Infrastructure is one of those core domains, and it should match the Study.

More Equipment Is Not Automatically Better

Sponsors care about appropriate capability. A long equipment list is less useful than demonstrating that the Site can execute the required procedures reliably.

8. Data Quality and Documentation

Enrollment alone does not define a successful Site. Sponsors also need reliable data. In the 2019 survey, 25% of respondents preferred that trial sites be best at good data entry, documentation, and reporting practice, and the authors note that data-quality factors seem highly valued especially in early-phase trials (Trials, 2019). Strong Sites develop disciplined processes for source documentation, query resolution, protocol compliance, and timely data entry.

9. Quality Oversight

A Sponsor may want to understand whether the Site has SOPs, training processes, internal quality checks, safety reporting workflows, and regulatory organization. The site-readiness framework above includes quality oversight and ethics and safety among its six core domains (Journal of Clinical and Translational Science, 2023). These systems reduce operational uncertainty.

10. Local Medical Community Support

This factor is often overlooked. A Site may have the required patient population but weak access because physicians do not refer, the protocol conflicts with local standard of care, competing treatments are readily available, or community clinicians are skeptical. The SASI deliberately assesses local medical community equipoise and colleague support (Contemporary Clinical Trials, 2024). A Site’s local relationships can therefore become part of its competitive advantage.

11. Referral Networks

Strong Sites often recruit beyond their own internal database. Potential referral sources include physician practices, specialists, hospitals, community clinics, and advocacy organizations. A Sponsor may gain confidence when the Site can explain where participants will actually come from.

12. Geographic Access

A potentially eligible participant still needs to reach the Site. Sponsors may consider population density, travel burden, location, transportation, and competing Sites. A Site should understand its recruitment geography — our article on geographic targeting in clinical trial recruitment discusses this in detail. Geography influences both feasibility and enrollment.

13. Diversity and Language Capability

Many Studies increasingly seek enrollment that better reflects affected populations. Sites may provide value through access to diverse communities, bilingual populations, and underserved geographic areas. But demographic access should be supported by actual operational capability — bilingual coordinators, localized materials, community relationships, and extended hours. As noted above, the SASI includes cultural and language competence training among its participant-access questions.

14. Site Capacity

A Site can be excellent and still be overloaded. Sponsors need to understand the active Study count, coordinator workload, screening capacity, and PI availability. A Site taking every available Study can eventually weaken performance. Strong Sites know their limits.

15. Competing Studies

Sponsors may ask whether you are already recruiting the same population, whether investigators are committed to another competing protocol, and whether participants will have multiple options. Sites should disclose competition realistically. Hiding it may create short-term opportunity but long-term performance problems.

16. Technology Capability

Technology increasingly matters, but not as a buzzword. Depending on the Study, Sponsors may evaluate the CTMS, the EHR environment, eSource compatibility, a recruitment CRM, remote participant workflows, and data systems. A 2023 eSource site-readiness survey of principal investigators, coordinators, and research information officers found that only 21% of sites were using FHIR standards to exchange patient data, and that organizations without a separate research IT group gave lower readiness-for-change ratings (Contemporary Clinical Trials, 2023). Technology matters when it supports the protocol.

17. Recruitment Technology

Sponsors may also value Sites capable of organizing digital acquisition, pre-screening, participant follow-up, referral tracking, and recruitment reporting. Again, capability matters more than software logos.

18. Participant Experience

A Site’s participant-facing operation matters. Sponsors want Studies that recruit and retain participants, and participant experience can influence responsiveness, retention, adherence, and willingness to return. Strong Sites build clear communication, reminders, bilingual support, and respectful follow-up.

19. Retention Matters Alongside Enrollment

Recruiting 30 participants means little if many leave prematurely. Sites should monitor retention, withdrawal, missed visits, and participant burden. Sponsors evaluate the entire Study journey.

20. Honest Feasibility

One of the strongest signals a Site can provide is realism. A Site saying “We can enroll 50” when the evidence suggests 10 creates risk. Site feasibility should be evidence-based — our article on feasibility strategy for independent Research Sites focused specifically on this process, and the 2026 framework above flags a circular-reasoning problem when Sites self-assess their own performance potential, which is one more reason to back every projection with data.

21. Communication Quality

Sponsors and CROs increasingly operate through complex global teams, and communication problems multiply quickly. A strong Site should be responsive, organized, clear, and accountable. The Site Feasibility Task Force documented communication gaps in both directions — Sites that do not respond to feasibility questions, and Sponsors and CROs that are slow to answer Site questions — and recommended clear communication channels and a plan for timely responses on both sides (Contemporary Clinical Trials Communications, 2024). Communication is not a soft skill. It is infrastructure.

22. Financial and Contract Readiness

Site selection may also be affected by the ability to move through budget negotiation, contracts, and payment setup. Long delays can affect activation. The Site should have clear internal ownership of these processes.

23. Regulatory Readiness

Sponsors want to know the Site can manage regulatory documentation, IRB processes, investigator documentation, and training records. Strong organization can reduce startup delays.

24. Site Leadership

A high-performing Site typically has operational leadership beyond the PI — a Site Director, an Operations Manager, or a Clinical Research Manager. Leadership helps coordinate staffing, recruitment, performance, and Sponsor communication. This can become increasingly important as the Site grows.

25. Adaptability

No Study runs exactly as expected. Recruitment changes, timelines shift, and protocols amend. Sponsors value Sites that can adapt without losing control. The 2026 framework above identifies dynamic capabilities — the Site’s ability to coordinate and adapt resources — as distinct from simply possessing resources (Therapeutic Innovation & Regulatory Science, 2026). That is a powerful distinction.

Having Resources Is Not the Same as Using Them Well

Two Sites may have similar investigators, the same equipment, and the same staff count, and one performs dramatically better. The difference may be how effectively the Site coordinates, responds, recruits, adapts, and communicates. Operational capability is more than inventory.

26. Proven Performance

Ultimately, Sponsors prefer evidence. A new Site may not have extensive history, and that does not automatically eliminate it. In the 2019 survey, 75% of respondents agreed their company would be interested in cooperating with an inexperienced trial site if it had access to a large patient population, and 52% had experienced their company selecting an inexperienced site over an experienced one because of a higher level of interest and commitment — although the authors note this applies primarily to late-phase trials (Trials, 2019). New Sites can compete, but they need to show readiness clearly.

27. Professionalism During Site Visits

When feasibility progresses to a pre-study or qualification visit, the Site should be ready. A 2025 primer for aspiring principal investigators describes the typical sequence: if initial feasibility looks promising, the Sponsor sets up a pre-study visit, tours the facility to check for adequate space and equipment, interviews the PI and staff about their plans to recruit and conduct the trial, and reviews regulatory binders or SOPs (Establishing a clinical trial site: a primer for aspiring principal investigators, 2025). The Site visit is where marketing claims meet reality.

28. Clear Differentiation

A Sponsor reviewing twenty Sites needs to remember why this one. The answer might be a bilingual population, CNS expertise, exceptional recruitment, a rare-disease network, fast startup, or rural access. Differentiation should come from real capability — our guide to how Research Sites can differentiate themselves covers how to build and prove it.

29. Evidence of Commitment

Sponsors do not want Sites that accept a Study and then deprioritize it. Signals of commitment may include PI engagement, a dedicated team, a realistic enrollment plan, internal ownership, and proactive communication. Commitment is a central theme of the standardized Site-assessment work cited above, which assesses site commitment time directly.

30. Ease of Working Together

There is an underrated factor: is this Site easy to work with? A Site that consistently provides clear answers, realistic timelines, organized documentation, and responsive communication reduces friction for the CRO. That matters.

What Sponsors Are Really Buying

A Sponsor is not simply selecting an address with an investigator. It is selecting an operational partner capable of converting a protocol into reliable execution. That partnership combines participants, people, processes, infrastructure, and performance.

A Practical Sponsor/CRO Readiness Checklist

Research Sites can evaluate themselves across these categories:

Investigator: Appropriate expertise? Available? Engaged?
Team: Enough coordinators? Relevant experience? Stable staffing?
Participants: Realistic population? Recruitment channels? Geographic access?
Operations: Required equipment? Enough capacity? Strong workflows?
Performance: Enrollment history? Data quality? Retention?
Timeline: Fast feasibility? Startup readiness? Responsive communication?
Technology: Appropriate Study systems? Recruitment tracking? Data capability?
Partnership: Easy to reach? Transparent? Reliable?

This is a much stronger framework than simply asking “Do we have enough patients?”

What Sites Should Communicate Before Selection

A Sponsor should be able to understand who your investigators are, which populations you can reach, how you recruit, what your Site can perform, how quickly you respond, and what you have achieved previously. The easier those answers are to verify, the stronger the Site’s position becomes. Our article on marketing a Research Site to Sponsors and CROs covers how to package those answers.

Do Not Try to Look Perfect

Every Site has limitations, and Sponsors understand that. A Site that transparently communicates its strengths and its constraints may be more credible than one claiming “we can do everything.” The goal is not perfection. It is predictability.

Site Selection Is Ultimately About Confidence

Sponsors and CROs are trying to answer one question: can we trust this Site to contribute successfully to the Study? Confidence grows from relevant experience, recruitment access, committed people, strong systems, realistic feasibility, reliable communication, and documented performance. Those are the signals Research Sites should work to build — and then make visible.

Frequently Asked Questions

What do Sponsors look for when selecting a Clinical Research Site?

Sponsors commonly evaluate investigator and team commitment, patient population, recruitment capability, Site resources, protocol fit, historical performance, operational readiness, timelines, and communication quality.

Is patient population the most important Site-selection factor?

It is important, but patient counts alone do not guarantee recruitment. Sponsors also consider access to participants, recruitment methods, Site capacity, investigator commitment, and protocol-specific realities.

Does prior Study experience matter?

Yes, but it is not the only factor. Sites with limited historical experience can still be competitive when they demonstrate appropriate investigators, participant access, operational readiness, commitment, and recruitment capability.

Why does responsiveness matter during Site selection?

Feasibility and startup operate under timelines. Slow communication can signal potential future operational delays.

Can a small independent Site compete with large Site networks?

Yes. Smaller Sites can differentiate through investigator involvement, specialization, local patient access, responsiveness, recruitment performance, flexibility, and strong execution.